Cancer Cell International (Oct 2022)

Outcome of autologous stem cell transplantation in patients with favorable-risk acute myeloid leukemia in first remission

  • Juan Chen,
  • Li Liu,
  • Runzhi Ma,
  • Aiming Pang,
  • Donglin Yang,
  • Xin Chen,
  • Jialin Wei,
  • Yi He,
  • Rongli Zhang,
  • Weihua Zhai,
  • Qiaoling Ma,
  • Erlie Jiang,
  • Mingzhe Han,
  • Jiaxi Zhou,
  • Sizhou Feng

DOI
https://doi.org/10.1186/s12935-022-02750-4
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Objective To evaluate the efficacy of autologous hematopoietic stem cell transplantation (auto-HSCT) in patients with favorable-risk acute myeloid leukemia in first remission. Method Twenty patients who received auto-HSCT at our center between January 2014 and January 2021 were retrospectively reviewed. Results Until last follow-up, three patients in the cohort were dead due to relapse. The estimated 1-year and 5-year overall survival were 95.00% ± 4.87% and 83.82% ± 8.58%, respectively. The estimated 5-year RFS and CIR (cumulative incidence of relapse) were 85.00% ± 7.98% and 15.00% ±7.98%, respectively. Conclusion The outcome of auto-HSCT in patients with favorable-risk acute myeloid leukemia in first remission was excellent and auto-HSCT could be an effective treatment for these patients.

Keywords